Compare SLN & ENVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLN | ENVX |
|---|---|---|
| Founded | 1994 | 2006 |
| Country | United Kingdom | United States |
| Employees | N/A | 664 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 678.0M | 741.7M |
| IPO Year | 2010 | 2020 |
| Metric | SLN | ENVX |
|---|---|---|
| Price | $14.82 | $3.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $42.60 | $13.61 |
| AVG Volume (30 Days) | 1.5M | ★ 8.3M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.94 |
| EPS | ★ N/A | N/A |
| Revenue | $559,000.00 | ★ $31,821,000.00 |
| Revenue This Year | N/A | $30.37 |
| Revenue Next Year | N/A | $238.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 37.91 |
| 52 Week Low | $4.19 | $3.06 |
| 52 Week High | $17.58 | $14.21 |
| Indicator | SLN | ENVX |
|---|---|---|
| Relative Strength Index (RSI) | 64.91 | 37.80 |
| Support Level | $13.01 | $3.06 |
| Resistance Level | $17.58 | $5.04 |
| Average True Range (ATR) | 0.68 | 0.28 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 96.32 | 14.91 |
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, the United States, Norway, Taiwan, and other regions.